Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Healthy
Interventions
sisunatovir, placebo, moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Cataract
Interventions
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Not listed Phase 4 Interventional Accepts healthy volunteers

A Study for Post op Inflammation After Cataract Surgery

NCT05665270
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1%
Drug
Lead sponsor
Wyse Eyecare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Northbrook, Illinois
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
12 Years and older
Enrollment
3,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more
Conditions
Postpartum Hemorrhage
Interventions
Carbetocin, Placebo, Placebo and Moxifloxacin
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Maxillary Sinusitis
Interventions
Telithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo, Moxifloxacin
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy Volunteer
Interventions
Moxifloxacin, RO4917838, RO4917838 placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Schizophrenia
Interventions
Elpipodect, Moxifloxacin, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Glendale, California • Orange, California • Hallandale, Florida + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough Corrected QT Interval Trial

NCT02073084
Conditions
Dyslipidemia
Interventions
K-877 Low Dose, Moxifloxacin, Placebo, K-877 High Dose
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

NCT00460759
Conditions
Mycobacterium Tuberculosis
Interventions
Moxifloxacin, Rifapentine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction - Oral Contraceptive

NCT00399685
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Conditions
Healthy Participants
Interventions
Aficamten, Aficamten-matching Placebo, Moxifloxacin
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Tuberculosis
Interventions
Moxifloxacin, PA-824, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Diabetes Mellitus, Type 2
Interventions
Ortho-Cyclen, Dulaglutide
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Obstetric Labour, Premature
Interventions
Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy
Interventions
lomitapide, EE/norgestimate
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of Energy Drinks on Cardiovascular Endpoints

NCT07212803
Conditions
Healthy Volunteers, Safety After Oral Intake
Interventions
Energy Drink A + Placebo Capsule, Placebo Drink + Moxifloxacin Capsule, Placebo Drink + Caffeine Capsule, Placebo Drink + Placebo Capsule, Energy Drink B, Control Product + Taurine, Control Product + Caffeine + Taurine, Lower Dose Energy Drink A
Dietary Supplement · Drug · Other
Lead sponsor
University of the Pacific
Other
Eligibility
18 Years to 40 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stockton, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Smoking, Sex Hormones, and Pregnancy

NCT01811225
Conditions
Nicotine Dependence, Contraception
Interventions
Low-dose Progesterone, High-dose Progesterone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Healthy Volunteer
Interventions
ESK-001, Moxifloxacin (400 mg), Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Cataract
Interventions
Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Drug
Lead sponsor
Inder Paul Singh, M.D.
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Venice, Florida • Racine, Wisconsin
Conditions
Tuberculosis
Interventions
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
Drug · Dietary Supplement
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas